Natriuretic peptides and the Framingham Risk score for screening of asymptomatic left ventricular systolic dysfunction in high-risk patients in primary care. The DAVID-BERG study

International Journal of Cardiology

Volumn 168, Issue 5, 2013, Pages 5093-5095

  Iacovoni, Attilio ^a   De Maria, Renata ^b   Gavazzi, Antonello ^a   Grosu, Aurelia ^a   Fontana, Alessandra ^a   Guideri, Silvia ^a   Gori, Mauro ^a   Ferrari, Paola ^a   Filippi, Alessandro ^c   Rutili, Maria Rosaria ^c   Donzelli, Luigi ^c   Parolini, Marina ^b   Senni, Michele ^a  

^a PAPA GIOVANNI XXIII HOSPITAL   (Italy)

^b OSPEDALE NIGUARDA CA GRANDA   (Italy)

^c Local Health Authority   (Italy)

Author keywords

Asymptomatic left ventricular systolic dysfunction; Cardiovascular risk; Heart failure; Natriuretic peptide; Primary care; Screening

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NATRIURETIC FACTOR; TRIACYLGLYCEROL;

ADULT; ASYMPTOMATIC DISEASE; BLOOD SAMPLING; CEREBROVASCULAR ACCIDENT; COMORBIDITY; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; FRAMINGHAM RISK SCORE; GLOMERULUS FILTRATION RATE; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART RATE; HIGH RISK PATIENT; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; LEFT VENTRICULAR SYSTOLIC DYSFUNCTION; LETTER; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL VASCULAR DISEASE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; RETINOPATHY; RISK ASSESSMENT; SCREENING TEST; VALVULAR HEART DISEASE; WAIST CIRCUMFERENCE;

ASYMPTOMATIC LEFT VENTRICULAR SYSTOLIC DYSFUNCTION; CARDIOVASCULAR RISK; HEART FAILURE; NATRIURETIC PEPTIDE; PRIMARY CARE; SCREENING;

AGED; ASYMPTOMATIC DISEASES; BIOLOGICAL MARKERS; COHORT STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDES; PRIMARY HEALTH CARE; PROSPECTIVE STUDIES; RISK FACTORS; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84886404684     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2013.07.260     Document Type: Article

References (9)

1. T.J. Wang, J.C. Evans, E.J. Benjamin, D. Levy, E.C. LeRoy, and R.S. Vasan Natural history of asymptomatic left ventricular systolic dysfunction in the community Circulation 108 2003 977 982
2. T.J. Wang, D. Levy, E.J. Benjamin, and R.S. Vasan The epidemiology of "asymptomatic" left ventricular systolic dysfunction: implications for screening Ann Intern Med 138 2003 907 916
3. M.M. Redfield, S.J. Jacobsen, J.C. Burnett, D.W. Mahoney, K.R. Bailey, and R.J. Rodeheffer Burden of systolic and diastolic dysfunction in the community. Appreciating the scope of the heart failure epidemic JAMA 289 2003 194 202
4. W.B. Kannel, R.B. D'Agostino, H. Silbershatz, A.J. Belanger, P.W. Wilson, and D. Levy Profile for estimating risk of heart failure Arch Intern Med 159 1999 1197 1204
5. M.M. Redfield, R.J. Rodeheffer, S.J. Jacobsen, D.W. Mahoney, K.R. Bailey, and J.C. Burnett Jr. Plasma brain natriuretic peptide to detect pre-clinical ventricular systolic or diastolic dysfunction: a community-based study Circulation 109 2004 3176 3181
6. G.I.W. Galasko, S.C. Barnes, P. Collinson, A. Lahiri, and R. Senior What is the most cost-effective strategy to screen for left ventricular systolic dysfunction: natriuretic peptides, the electrocardiogram, hand-held echocardiography, traditional echocardiography, or their combination? Eur Heart J 27 2006 193 200
7. R.S. Vasan, E.J. Benjamin, and M.G. Larson Plasma natriuretic peptides for community screening for left ventricular hypertrophy and systolic dysfunction: the Framingham heart study JAMA 288 2002 1252 1259
8. P.M. McKie, A. Cataliotti, and B.D. Lahr The prognostic value of N-terminal pro-B-type natriuretic peptide for death and CV events in healthy normal and stage A/B heart failure subjects J Am Coll Cardiol 55 2010 2140 2147
9. S. Gupta, A. Rohatgi, and C.R. Ayers Risk scores versus natriuretic peptides for identifying prevalent stage B heart failure Am Heart J 161 2011 923 930